Form D · Pharmaceuticals
Phosplatin Therapeutics Inc.
New York, NY · CIK 0001757705
Offering snapshot reported Dec 15, 2021 · SEC filing
- Reported sold
- $37.3M Offering amount: $37.3M
- Investors reported
- 41 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 3, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 15, 2021 | Initial | $37,295,619 | No comparison | 41 | SEC filing |
| Aug 14, 2020 | Initial | $18,400,000 | No comparison | 40 | SEC filing |
| Nov 8, 2018 | Initial | $16,605,000 | No comparison | 48 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-425067
Source: Form D, filed Dec 15, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Frances Bonham | Executive |
| John Caouette | Director |
| Peter Espig | Director |
| Robert Fallon | Director, Executive |
| Rosita Leong | Director |
| John Porter | Director |
| Matthew Price | Director |
| Fallon Robert | Director, Executive |
| Charles Stuckey | Director |
| Neil Sunderland | Director |
| Elizabeth Tallett | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1350 Avenue Of The Americas 23rd Floor
New York, NY, 10019
New York, NY, 10019